Healthcare Industry News: Allergan
News Release - April 11, 2006
CoTherix Appoints Abhay Joshi as EVP and Chief Technical OfficerSOUTH SAN FRANCISCO, Calif., April 11 (HSMN NewsFeed) -- CoTherix, Inc. (Nasdaq: CTRX ) today announced the appointment of Abhay Joshi, Ph.D. as Executive Vice President and Chief Technical Officer, effective immediately. Dr. Joshi has over seventeen years of global manufacturing operations and product and process development experience in biologics, pharmaceutical and medical device industries in the United States, Europe, Latin America and Asia. Dr. Joshi will be responsible for the overall management of CoTherix's technical operations including lifecycle development and planning.
"Abhay brings to CoTherix a wealth of technical experience and an extraordinary record of achievement," stated Donald J. Santel, Chief Executive Officer of CoTherix. "His experience will be invaluable as he contributes to our plans for pipeline expansion, both through formulation enhancements to Ventavis as well as in-licensing."
Dr. Joshi most recently served as the Vice President of Global Technical Operations, Specialty Pharmaceuticals at Allergan, Inc. At Allergan, he managed the Company's global biologics manufacturing operations for BOTOX® and also managed Allergan's Latin America and Asia Pacific pharmaceutical operations.
Dr. Joshi received his BTech in Chemical Engineering from the Indian Institute of Technology, New Delhi. He also earned an MSE and a Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, and received an MBA from the University of California, Irvine. Dr. Joshi holds an adjunct faculty appointment at the University of Southern California School of Pharmaceutical Sciences and is a member of the Industrial Society of Pharmaceutical Engineers.
About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. CoTherix's Ventavis® (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class III or IV symptoms (World Health Organization Group I). PAH is a highly debilitating and potentially fatal disease characterized by high blood pressure in the pulmonary arteries of the lungs. Ventavis is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclins. CoTherix, the CoTherix logo and REVEAL Registry are trademarks of CoTherix, Inc. Ventavis is a registered trademark of Schering AG, Germany. More information can be found at www.cotherix.com and www.4Ventavis.com
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding the company's expectations, beliefs, hopes, goals, plans, intentions, initiatives or strategies, including statements regarding Dr. Joshi's experience and responsibilities, and our plans for pipeline expansion through formulation enhancement and in-licensing activities. All forward-looking statements included in this press release are based upon information available to CoTherix as of the date hereof, and the company assumes no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Actual events could differ materially from expectations. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors" section of CoTherix's most recent annual report on Form 10-K filed with the Securities and Exchange Commission.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.